It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Retention of 18F-Flortaucipir is reportedly increased in the semantic variant of primary progressive aphasia (svPPA), which is dominated by TDP-43 pathology. However, it is unclear if 18F-Flortaucipir is also increased in other TDP-43 diseases, such as bvFTD caused by a C9orf72 gene mutation. We therefore recruited six C9orf72 expansion carriers, six svPPA patients, and 54 healthy controls. All underwent 18F-Flortaucipir PET and MRI scanning. Data from 39 Alzheimer’s Disease patients were used for comparison. PET tracer retention was assessed both at the region-of-interest (ROI) and at the voxel-level. Further, autoradiography using 3H-Flortaucipir was performed. SvPPA patients exhibited higher 18F-Flortaucipir retention in the lateral temporal cortex bilaterally according to ROI- and voxel-based analyses. In C9orf72 patients, 18F-Flortaucipir binding was slightly increased in the inferior frontal lobes in the ROI based analysis, but these results were not replicated in the voxel-based analysis. Autoradiography did not show specific binding in svPPA cases or in C9orf72-mutation carriers. In conclusion, temporal lobe 18F-Flortaucipir retention was observed in some cases of svPPA, but the uptake was of a lower magnitude compared to AD dementia. C9orf72-mutation carriers exhibited none or limited 18F-Flortaucipir retention, indicating that 18F-Flortaucipir binding in TDP-43 proteinopathies is not a general TDP-43 related phenomenon.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Lund University, Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Skåne University Hospital, Department of Neurology, Lund, Sweden (GRID:grid.411843.b) (ISNI:0000 0004 0623 9987)
2 Lund University, Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
3 Clinical Sciences Helsingborg, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
4 Lund University, Department of Psychology, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)
5 Erasmus Medical Centre, Department of Neurology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)
6 Roche Pharmaceutical Research and Early Development, Neuroscience Translational Technologies, Roche Innovation Center, Basel, Switzerland (GRID:grid.5645.2)
7 Lund University, Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Memory Clinic, Skåne University Hospital, Malmö, Sweden (GRID:grid.411843.b) (ISNI:0000 0004 0623 9987)